Abbott Laboratories (ABT) Balance Sheet
As of 2026-06-30 (10-Q), Abbott Laboratories (ABT) reported total assets of $109.2B and shareholders' equity of $51.1B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $5.1B. Long-term debt: $29.6B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABTAbbott LaboratoriesFollow ABT — free
—
Price chart with a free account
- Market cap
- 179.4B
- P/E TTM
- 33.5
- Dividend yield
- 2.4%
- 52-week
- —
- Next earnings
- 20 Jan, in 88 days
| Line | FY2007 Dec 07 | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.46 | 8.81 | 3.65 | 6.81 | 10.80 | 3.48 | 4.06 | 5.00 | 18.62 | 9.41 | 3.84 | 3.86 | 6.84 | 9.80 | 9.88 | 6.90 | 7.62 | 8.52 | 5.10 | |
| Short-term investments | 0.36 | 1.12 | 1.80 | 1.28 | 4.37 | 4.62 | 0.40 | 1.12 | 0.16 | 0.20 | 0.24 | 0.28 | 0.31 | 0.45 | 0.29 | 0.38 | 0.35 | 0.42 | 0.50 | |
| Receivables | 4.95 | 6.54 | 7.18 | 7.68 | 7.61 | 3.99 | 3.59 | 3.42 | 3.25 | 5.25 | 5.18 | 5.43 | 6.41 | 6.49 | 6.22 | 6.57 | 6.93 | 7.93 | 8.60 | |
| Inventory | 2.95 | 3.26 | 3.19 | 3.28 | 3.79 | 2.69 | 2.64 | 2.60 | 2.43 | 3.60 | 3.80 | 4.32 | 5.01 | 5.16 | 6.17 | 6.57 | 6.19 | 6.49 | 7.32 | |
| Current assets | 14.04 | 23.31 | 22.32 | 23.77 | 31.32 | 19.25 | 13.56 | 14.16 | 26.78 | 20.15 | 14.63 | 15.67 | 20.44 | 24.24 | 25.22 | 22.67 | 23.66 | 26.00 | 24.52 | |
| Total assets | 39.71 | 52.58 | 60.57 | 60.28 | 67.24 | 42.94 | 41.21 | 41.25 | 52.67 | 76.25 | 67.17 | 67.89 | 72.55 | 75.20 | 74.44 | 73.21 | 81.41 | 86.71 | 109.22 | |
| Current liabilities | 9.10 | 13.05 | 17.26 | 15.48 | 13.28 | 9.51 | 10.47 | 9.19 | 6.66 | 8.91 | 9.01 | 10.86 | 11.91 | 13.11 | 15.49 | 13.84 | 14.16 | 16.50 | 17.81 | |
| Long-term debt | 9.49 | 11.27 | 12.52 | 12.04 | 18.09 | 3.39 | 3.39 | 5.87 | 20.68 | 27.21 | 19.36 | 16.66 | 18.53 | 17.30 | 14.52 | 13.60 | 12.63 | 9.90 | 29.60 | |
| Short-term debt | 0.90 | 0.21 | 2.04 | 1.03 | 0.31 | 0.01 | 0.06 | 0.00 | 0.00 | 0.51 | 0.01 | 1.28 | 0.01 | 0.75 | 2.25 | 1.08 | 1.50 | 3.03 | 3.01 | |
| Shareholders' equity | 17.78 | 23.14 | 22.68 | 24.44 | 26.72 | 25.17 | 21.53 | 21.21 | 20.54 | 30.90 | 30.52 | 31.09 | 32.78 | 35.80 | 36.69 | 38.60 | 47.66 | 52.13 | 51.11 |
USD billions · SEC XBRL
Abbott Laboratories — questions
- How much cash does Abbott Laboratories have?
- $5.1B in cash and cash equivalents as of 2026-06-30.
- How much debt does Abbott Laboratories have?
- $29.6B of long-term debt and $3.0B due within a year as of 2026-06-30.
- What are Abbott Laboratories's total assets?
- $109.2B as of 2026-06-30.
- What is Abbott Laboratories's shareholders' equity?
- $51.1B as of 2026-06-30.
Every figure on this page comes from Abbott Laboratories's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.